GlucoTrack's Q1 net loss narrows

GlucoTrack

14/05/2026 22:36

Overview

US medical device maker's Q1 net loss narrowed yr/yr, driven by reduced derivative liabilities

Company submitted IDE application to FDA, targeting U.S. clinical trial launch in 2H 2026

Debt reduced and cash position strengthened via note conversion and credit facility draw

Outlook

GlucoTrack targets U.S. clinical trial launch for CBGM in 2H 2026

Company plans to present clinical data at industry conferences as available

GlucoTrack expects cash runway into early Q3 2026, supporting trial initiation

Result Drivers

R&D SPENDING - Higher research and development expenses were attributed to timing in product and manufacturing development activities

ADMINISTRATIVE COSTS - General and administrative expenses rose due to increased professional fees and personnel costs

DERIVATIVE LIABILITIES - Net loss narrowed mainly due to a reduction in non-cash change in derivative liabilities

Company press release: ID:nGNX39QtgS

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$4.33 mln
Q1 Operating Income
-$4.20 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)